Efficacy of pharmacological interventions in COVID-19 : A network meta-analysis
© 2022 British Pharmacological Society..
AIMS: To perform network meta-analysis for a head-to-head comparison of various interventions used in coronavirus disease 2019 (COVID-19) on mortality, clinical recovery, time to clinical improvement and the occurrence of serious adverse events.
METHODS: Systematic search was performed using online databases with suitable MeSH terms including coronavirus, COVID-19, randomized controlled trial, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, remdesivir, favipiravir, dexamethasone and interferon-β. Data were independently extracted by 2 study investigators and analysed.
RESULTS: Out of 1225 studies screened, 23 were included for qualitative and quantitative analysis. Among the drugs studied, dexamethasone reduces mortality by 10%, with a relative risk of 0.90 (95% confidence interval [0.82-0.97]) and increases clinical recovery by 6% (relative risk 1.06, 95% confidence interval [1.02-1.10]) compared to standard of care. Similarly, remdesivir administered for 10 days increased clinical recovery by 10%, reduced time to clinical improvement by 4 days and lowered the occurrence of serious adverse events by 27% as compared to standard of care.
CONCLUSION: In comparison to standard of care, dexamethasone was found to increase clinical recovery and lower mortality; remdesivir was significantly associated with a lower risk of mortality as compared to tocilizumab and higher clinical recovery and shorter time to clinical improvement as compared to hydroxychloroquine and tocilizumab; remdesivir followed by tocilizumab were found to have lesser occurrence of serious adverse events in patients with moderate to severe COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:88 |
---|---|
Enthalten in: |
British journal of clinical pharmacology - 88(2022), 9 vom: 07. Sept., Seite 4080-4091 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Selvarajan, Sandhiya [VerfasserIn] |
---|
Links: |
---|
Themen: |
2494G1JF75 |
---|
Anmerkungen: |
Date Completed 19.08.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/bcp.15338 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM338870520 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM338870520 | ||
003 | DE-627 | ||
005 | 20231226001636.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bcp.15338 |2 doi | |
028 | 5 | 2 | |a pubmed24n1129.xml |
035 | |a (DE-627)NLM338870520 | ||
035 | |a (NLM)35357033 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Selvarajan, Sandhiya |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy of pharmacological interventions in COVID-19 |b A network meta-analysis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.08.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 British Pharmacological Society. | ||
520 | |a AIMS: To perform network meta-analysis for a head-to-head comparison of various interventions used in coronavirus disease 2019 (COVID-19) on mortality, clinical recovery, time to clinical improvement and the occurrence of serious adverse events | ||
520 | |a METHODS: Systematic search was performed using online databases with suitable MeSH terms including coronavirus, COVID-19, randomized controlled trial, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, remdesivir, favipiravir, dexamethasone and interferon-β. Data were independently extracted by 2 study investigators and analysed | ||
520 | |a RESULTS: Out of 1225 studies screened, 23 were included for qualitative and quantitative analysis. Among the drugs studied, dexamethasone reduces mortality by 10%, with a relative risk of 0.90 (95% confidence interval [0.82-0.97]) and increases clinical recovery by 6% (relative risk 1.06, 95% confidence interval [1.02-1.10]) compared to standard of care. Similarly, remdesivir administered for 10 days increased clinical recovery by 10%, reduced time to clinical improvement by 4 days and lowered the occurrence of serious adverse events by 27% as compared to standard of care | ||
520 | |a CONCLUSION: In comparison to standard of care, dexamethasone was found to increase clinical recovery and lower mortality; remdesivir was significantly associated with a lower risk of mortality as compared to tocilizumab and higher clinical recovery and shorter time to clinical improvement as compared to hydroxychloroquine and tocilizumab; remdesivir followed by tocilizumab were found to have lesser occurrence of serious adverse events in patients with moderate to severe COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a clinical recovery | |
650 | 4 | |a dexamethasone | |
650 | 4 | |a hydroxychloroquine | |
650 | 4 | |a mortality | |
650 | 4 | |a remdesivir | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a Hydroxychloroquine |2 NLM | |
650 | 7 | |a 4QWG6N8QKH |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
700 | 1 | |a Anandaradje, Annuja |e verfasserin |4 aut | |
700 | 1 | |a Shivabasappa, Santhosh |e verfasserin |4 aut | |
700 | 1 | |a Melepurakkal Sadanandan, Deepthy |e verfasserin |4 aut | |
700 | 1 | |a Nair, N Sreekumaran |e verfasserin |4 aut | |
700 | 1 | |a George, Melvin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 88(2022), 9 vom: 07. Sept., Seite 4080-4091 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
773 | 1 | 8 | |g volume:88 |g year:2022 |g number:9 |g day:07 |g month:09 |g pages:4080-4091 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15338 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 88 |j 2022 |e 9 |b 07 |c 09 |h 4080-4091 |